Zynaxis other research news

ZNXS (Malvern, Penn.) reported activity against ovarian and other cancers in mice. Survival time was increased two-fold after treatment with conjugates of doxorubicin. The conjugates were given by a single intraperitoneal injection a day after tumor was implanted.

Conjugate Zyn 198 demonstrated no toxicity at a dose equivalent of free doxorubicin that normally would be lethal. No additive lethality with adriamycin was found, while disease-free survival was extended. Zyn 198 was active in mouse and human ovarian tumor, and Lewis lung tumor. ...